Zika virus (ZIKV) infection in pregnancy is associated with adverse fetal outcomes, such as microcephaly and other congenital malformations. No therapeutic options are available to pregnant women with ZIKV infection to prevent these effects. Drug trials in pregnancy raise several scientific, ethical, and logistic challenges, which are compounded further in ZIKV because of limited knowledge of the disease pathophysiology and a product development pipeline in its infancy. We evaluate the major challenges in choosing therapeutics to prevent congenital ZIKV disease and conducting clinical trials of these treatments, with a focus on preventing congenital central nervous system malformations. These challenges must be characterized and planned for now so that clinical trials can progress expediently and effectively in the future.
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Z ika virus (ZIKV) is a flavivirus transmitted by the
Aedes mosquito (1) . As of 29 December 2016, 75 countries, including the United States, reported mosquito-borne transmission (2) . The evidence for a causal association between maternal ZIKV infection and congenital malformations is now accepted (3) . A more extensive spectrum of birth defects, including central nervous system (CNS), genitourinary, gastrointestinal, and cardiac malformations, likely will become apparent over time (4) . The World Health Organization (WHO) recently announced an emergency, fast-tracked research and development agenda, including the need for ZIKV therapeutics to be evaluated in clinical trials (5) . Trials of therapeutics in nonpregnant adults would offer limited estimates of safety and effectiveness in preventing adverse fetal outcomes; therefore, trials in pregnant women are specifically needed. However, drug trials in pregnancy raise ethical, scientific, and logistical challenges (6) , which are compounded in ZIKV because of limited knowledge of the epidemiology and pathogenesis of adverse fetal outcomes. We discuss the issues surrounding the choice and investigation of therapeutics to prevent congenital ZIKV disease (CZD), with a focus on CNS malformations.
CANDIDATE DRUG SELECTION
The theoretical mechanisms by which maternal ZIKV infection disrupts fetal CNS development are numerous and complex (Figure) . A major obstacle to choosing therapies for research is our limited understanding of the predominant mechanisms underlying CZD, intrauterine growth restriction (IUGR), and fetal loss (7) . In this section, we discuss some general aspects pertinent to drug selection.
Targeting Viral Replication
Targeting viral replication is an upstream approach that avoids narrowly targeting only one of several potential pathogenic downstream consequences of infection ( Figure) . It also prevents some of the risks associated with targeting host factors (discussed later). The full spectrum of congenital disease likely is broader than currently appreciated and may not become apparent until childhood. Several factors, including host responses, nutritional factors, and inoculation dose, may influence this spectrum. Directly inhibiting viral replication would minimize the therapeutic variability among individuals as a result of such factors.
Direct-acting antiviral small molecules are prime candidates for investigation. High-throughput screens and computational drug discovery have led to identification of candidate drugs for dengue, a related flavivirus (8) . Drug repurposing therefore may be an efficient approach and has been used in other epidemics, such as the Ebola outbreak (9) . Priority should be given to antiviral and nonantiviral drugs that have shown in vitro activity against other flaviviruses and Flaviviridae and have already been approved by regulatory agencies in other contexts (8) . Several drugs approved by the U.S. Food and Drug Administration (FDA), some of which have activity against dengue, hepatitis C, chikungunya, and Japanese encephalitis, were recently screened for anti-ZIKV activity (10 -13). Sofosbuvir (11) , niclosamide (12) , ivermectin (13), mefloquine (13), daptomycin (13), bortezomib (13), and mycophenolic acid (13), among others, have anti-ZIKV activity in vitro. The viral polymerase inhibitor 7-deaza-2'-C-methyladenosine also has in vivo activity against ZIKV in mice (10). The use of ZIKV-specific, target-based chemogenomic approaches would help further narrow the list of promising candidates for testing in vitro and in vivo (8) .
Targeting Host Neural Receptors for the Virus
Zika virus has been isolated from brain tissues of human fetuses with microcephaly (14) , confirming that fetal infection may occur. The virus may be transferred via placental infection or by passage across the placenta (15), followed by entry into the CNS and replication within neurons and glia (16) . Although the cell surface receptors by which ZIKV enters neurons have not yet been fully functionally characterized, AXL is a key receptor for viral entry into other cells (such as fibroblasts and dendritic cells) (17) , and AXL and other putative flavivirus entry receptors are strongly expressed in neural stem cells (NSCs) of the developing brain (18) . In vitro human cell and in vivo mouse studies have demonstrated that ZIKV preferentially infects forebrain-specific NSCs, resulting in cell death, cell-cycle dysregulation, and microcephaly (19, 20) . Although prolonged ZIKV infection of the fetoplacental unit may occur (14) , persistence of virus within the fetal CNS may not be necessary for microcephaly to result. The stem cell pool has a finite ability to regenerate (21); therefore, partial destruction of the NSC pool may have cascading consequences on brain development throughout gestation. Primary microcephaly itself is hypothesized to result from depletion of the founder NSC populations (22) . These findings highlight AXL, as well as other entry receptors, as an investigative target for blockade. However, normal AXL signaling supports various aspects of CNS development and function (23) , making it a problematic target. More generally, because many flavivirus entry receptor genes likely play a role in normal CNS development (24), targeting them is an unpredictable strategy.
Targeting the Host Immune Response
Both fetal and maternal immune responses may have profound effects on fetal neurodevelopment (25, 26) . The development of the fetal immune system begins in earnest in the second trimester (27) , suggesting that the fetal immune response to ZIKV likely does not play a substantial role in disease during early maternal ZIKV infection. However, the spectrum of congenital malformations is potentially wide, and congenital disease may occur as a result of mid to late maternal infection (4), raising the possibility of several pathogenic mechanisms. Maternal immune factors also might play a role at any stage of pregnancy.
For example, ZIKV-induced activation of Toll-like receptor 3 (TLR3) results in stunted growth of human embryonic stem cell-derived cerebral organoids (an in vitro model for human embryonic CNS development) (28) , which is prevented by TLR3 inhibition (28) . In the CNS, TLR3 is a key innate immune antiviral pathogen recognition receptor (29) , whose activation results in the transcription of genes involved in both immunity (29) and neuronal development (Salam AP. Unpublished data). Besides TLR3 signaling, other immune pathways likely are activated by ZIKV, and some of them also will disrupt CNS development (30) . Thus, targeting host immune pathways may represent a therapeutic strategy for preventing disruption of CNS development. However, unperturbed TLR3 and CNS immune function play a critical role in CNS development (30) ; therefore, any attempt to modulate TLR3 function in utero, as with AXL, may lead to unpredictable consequences.
Targeting Placental Dysfunction
Altered placental function due to placental infection or maternal immune factors may lead to the release of placental immune factors that are neurotoxic to the fetus or disrupt the synthesis of placental molecules necessary for healthy embryonic development (15) . In pregnant mice, systemic ZIKV infection results in placental damage and insufficiency, leading to IUGR, fetal loss, and microcephaly (20, 31) . In addition, ZIKV impairs placental autophagy (17) , which normally limits viral replication (32) . Placental vulnerability to infections seems pronounced early in pregnancy (33) , consistent with the greatest risk for microcephaly occurring during ZIKV infection in the first and early second trimesters (34) . Like targeting the host immune response or cell entry receptors, however, placental function exists in a delicate homeostatic balance (35) ; therefore, modulation of placental function is potentially unpredictable. Several animal studies, however, successfully tested the feasibility of targeting placental dysfunction in the context of preeclampsia and IUGR. Human clinical trials investigating the effects of such agents as arginine, sildenafil, pravastatin, and oxygen supplementation therapy on IUGR are ongoing (36) .
The Use of Pathogen-Specific Antibodies
The administration of pathogen-specific antibodies (PSAs), such as human convalescent plasma or human immune globulin, is established for several infections in general (37) and, to a limited extent, for some during pregnancy (38, 39) . Pathogen-specific antibodies bind to ligands on viral surfaces, preventing the virus from 
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entering cells ("neutralization") or activating the immune system, resulting in viral destruction and lysis of infected cells. In immunologically naive persons, PSAs are used to prevent maternal measles and varicellazoster virus after exposure (38, 39) ; however, evidence that PSAs can prevent or limit the adverse consequences of established maternal infection on fetal outcomes is inconclusive. For example, administration of cytomegalovirus (CMV)-specific hyperimmune globulin in maternal primary CMV infection was associated with reduced maternal-to-fetal transmission and congenital infection severity in several prospective, observational studies (40 -42) . Nevertheless, a recent small-scale randomized trial failed to demonstrate a statistically significant benefit (43); however, the researchers did not assess hearing loss in infants (a common consequence of maternal CMV infection), the study may have been underpowered, the timing of primary CMV infection relied partly on subject recall, and a delay of up to 6 weeks occurred between the estimated primary infection and therapy. Two larger phase 3 trials are ongoing (44, 45) . One benefit of the use of nonengineered PSAs is their relative safety. The most serious side effects are transfusion reactions, but these are rare. In addition, PSAs generally are considered safe for the fetus (46), which highlights them as a potential "ready-to-go" therapeutic candidate. Given their approved use in other maternal infections, PSAs may not have to undergo additional preclinical safety testing. The main limitations of nonengineered PSAs are primarily logistic and include issues surrounding collection, storage, and transport. Further, in vitro evidence suggests that antidengue antibodies may result in antibody-dependent enhancement of ZIKV replication (47); therefore, the donor pool may be required to have high anti-ZIKV antibody but low or absent anti-dengue antibody titers. This donor pool may be difficult to populate given that dengue is endemic in the most affected country, Brazil (48) . Although engineered PSAs against ZIKV would circumvent this issue, they would require extensive preclinical and clinical safety testing.
Pharmacokinetics and Pharmacodynamics in Pregnancy
Pregnancy results in dramatic physiologic changes that affect drug absorption, distribution, metabolism, and excretion (49). Elevated progesterone levels prolong small-bowel transit time by 30% to 50% (49). Hemodilutional hypoalbuminemia (49) affects drug bioavailability. Hormonal alterations in drug-metabolizing enzymes (49) and changes in renal blood flow (49) affect drug metabolism and clearance. Further, the chemical characteristics of drugs affect the way they cross the placenta, including simple diffusion, facilitated diffusion, pinocytosis, and active transport (50) . Thus, for de novo ZIKV therapeutic agents and some repurposed drugs, substantial preclinical research using models of human placental function will be required. Placental function shows dramatic interspecies variation (51), limiting our ability to draw definitive conclusions from animal models alone. In vitro models, such as explants of human placenta, may offer additional insights (52) . Placental infection and inflammation may alter drug and immunoglobulin passage across the placenta (53) , and preclinical testing should include models of placental function in the context of ZIKV infection. Whether a ZIKV therapeutic agent crossing the placenta, as well as the fetal blood-brain barrier, is desirable will depend on the therapeutic strategy. Our understanding of human fetal blood-brain barrier development is very limited, however, and complicated by the fact that inflammation may alter bloodbrain barrier permeability (54) .
Therefore, maternal pharmacokinetic monitoring of any therapeutic agent is important. Pharmacokinetic monitoring of PSAs may be complicated by crossreactivity with other flavivirus antibodies. Fetal pharmacokinetic monitoring would be advantageous depending on the therapeutic strategy and target, although it requires amniotic fluid sampling, which is invasive, requires trained personnel, and has risks. If therapy were to continue close to delivery, umbilical cord blood might be sampled for pharmacokinetic monitoring.
Teratogenic Risk
Some of the candidate agents identified by drug repurposing screens cross the placenta and are rated as class B by the FDA, meaning that animal reproduction studies failed to demonstrate fetal risk, and no adequate, well-controlled studies were done in pregnant women. In view of the limitations of rodents as a model for human CNS development, nonhuman primate models may be needed (55); however, preclinical testing in such models is lengthy and limited by small numbers of animals. Predictive drug-target gene models of clinical teratogenicity might help prioritize the spectrum of candidate drugs for repurposing (56) . For example, drugs with medium in vitro and in vivo efficacy but low predicted teratogenic risk might take priority over those with high in vitro and in vivo efficacy but medium-high predicted teratogenic risk.
The knowledge threshold for teratogenic risk ideally would be as-if not more-stringent as normally expected; however, a strict threshold might severely limit the choice of therapeutic agents that could be studied. Thus, conducting a clinical trial of a drug for which slightly less information than usual is available regarding teratogenic risks may be appropriate. Either way, the actual risk for teratogenicity associated with any drug has to be balanced against the risk for CZD. Accepting a higher-than-normal risk for teratogenicity may be appropriate, as long as the risk is lower than that for severe CZD. Thus, therapeutics with a low risk for major teratogenicity or medium risk for minor teratogenicity still may benefit fetuses at high risk for severe CZD. Defining the fetal populations with the greatest risk for severe malformations therefore is critical. Table 1 suggests an appropriate study population. Several knowledge gaps exist that limit the precise definition of the group most likely to benefit. When the virus crosses the placenta following maternal infection (15) , how long viral replication persists in the mother and fetus (14) and whether latent viral reservoirs exist within the mother and fetus are unknown (57) . Whether the development of microcephaly depends on prolonged exposure of the fetus to ZIKV or whether only a short period of exposure is necessary to initiate a cascade of developmental disruption is unclear. Initial therapeutic trials therefore should focus on inhibiting viral replication in symptomatic pregnant women with evidence of acute ZIKV infection. Although fetal malformations occur in asymptomatic maternal infections (58), screening asymptomatic women regularly during pregnancy (for example, at least weekly) as an initial trial strategy would be logistically demanding. Screening or prophylaxis in high-risk asymptomatic women might be a viable strategy in the future.
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STUDY POPULATION
Serologic assays should not be used to confirm infection because of cross-reactivity with other flaviviruses and the predicted time course of anti-ZIKV antibody responses (59). Also, they offer no information regarding ongoing viral replication. A positive ZIKV polymerase chain reaction (PCR) test in blood or urine therefore should be considered as evidence of infection. Patients with co-infections, such as dengue or chikungunya, should be excluded, and a multiplex PCR test for ZIKV, dengue, and chikungunya would be useful. However, PCR assays also are limited in their ability to assess viral clearance, because undetectable RNA in blood or urine does not exclude ongoing replication in other compartments. Because antibody-dependent enhancement may enhance ZIKV infection, patients with evidence of previous dengue infection (that is, positive IgG but negative IgM and PCR) may be among those who benefit the most from therapy.
A sensible limit on time elapsed between symptom onset and start of therapy will need to be defined. Starting therapy too soon would limit study enrollment and potential translatability to clinical practice; waiting too long might result in therapy being started too late to prevent congenital disease. Different therapeutic targets and agents likely have different therapeutic time windows; for example, PSAs seem to work best when given very early in the disease course (60) . In general, we suggest choosing a relatively narrow time window between symptom onset and the beginning of therapy, ideally 72 hours. The time frame also will depend on the local health infrastructure and study logistics and may not represent a viable, real-world clinical strategy. One potential way to limit this challenge is to enroll seronegative pregnant women in high-transmission areas at their first prenatal clinic visit (with instructions to contact the study team if they develop symptoms). A more realistic time frame may be up to 5 days, which might be extended further with the explicit aim of determining the point at which therapy is no longer effective. Large sample sizes would be needed to perform subgroup analyses according to time to therapy.
Women infected in the first and early second trimesters likely would benefit the most, given the course of fetal development (61) and suggestions that the risk for congenital malformations is greatest in early pregnancy (34) . Therefore, initial trials should focus on these periods while further epidemiologic data are awaited. Whether virus persists in maternal latent sites (57) raises the question of whether a single course of therapy is sufficient or whether therapy should be repeated. In the case of CMV infection, for example, hyperimmune globulin is administered at monthly intervals throughout pregnancy. This is a critical question that must be addressed. One option may be a randomized 3-group study design: placebo versus single dosing versus multiple dosing. Because of their long half-lives, PSAs may offer an advantage over other therapeutics (62) by obviating the need for daily or weekly dosing. Administering PSAs monthly also might circumvent the theoretical issue of maternal susceptibility to ZIKV reinfection, given the course of immune changes during pregnancy (63) . However, multiple PSA doses may increase the risk for antibody-dependent enhancement of ZIKV disease.
STUDY END POINTS
At the very least, primary end points should include miscarriage or stillbirth, presence and degree of IUGR, and presence and degree of microcephaly. The WHO defines microcephaly as an occipitofrontal circumference greater than 2 SDs below the mean (64); however, this definition is somewhat controversial, and other criteria have been used (65) . On the basis of the WHO definition, 2% of the general population would be classified as having microcephaly, even though these persons simply are at the low end of the population distribution (66) . Furthermore, occipitofrontal circumference is an indirect measure, and microencephaly 
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(an abnormally small brain) may be present despite normal occipitofrontal circumference. Regional structural changes also likely affect prognosis (67) . For these reasons, secondary end points should include magnetic resonance imaging and ultrasonographic assessments in newborns to identify agyria, lissencephaly, ventriculomegaly, intracranial calcifications, and other abnormalities (68) . The use of imaging analytics should be standardized among studies, and consensus will be required to define and grade microcephaly and neuroimaging findings. Additional secondary end points include adverse drug events; degree and duration of maternal viremia (including recurrence); viremia in amniotic fluid; virologic and immunohistologic findings in the placenta; gestational age at delivery; and presence of congenital defects, such as cleft lip, gastroschisis, spina bifida, and heart defects, in newborns. A consistent, consensusbased system for identifying and recording birth defects will be required (69). Fetal ultrasonography should be used to monitor therapeutic efficacy and safety; however, determining whether rare congenital defects are the result of ZIKV or a drug side effect will be challenging. Furthermore, because congenital malformations should be characterized by degree of severity, their identification on ultrasonography despite ongoing therapy would not necessarily imply complete treatment failure. Similarly, detection of ZIKV in amniotic fluid may not necessarily predict treatment failure, because the level of virus in amniotic fluid may determine the risk for complications, as in CMV (70) . Thus, a threshold for detectable virus may exist below which therapy likely will still be effective and should continue. Other secondary end points should include epilepsy and neurodevelopmental delays, including vision and hearing defects during the first year of life and ideally throughout childhood. Again, consensus will be required regarding which neurodevelopmental screening tools to use, and their use should be standardized across observational and therapeutic studies. Sampling of neonatal cerebrospinal fluid for ZIKV RNA should be considered.
Maternal safety monitoring will vary according to the therapeutic agent studied but should, at a minimum, include monitoring of hematologic indices as well as renal and liver function. However, normal pregnancy is associated with several changes in blood indices, including anemia and thrombocytopenia (49), mild increases in alanine and aspartate aminotransferase levels, and marked increases in alkaline phosphatase levels during the third trimester (49), and these changes may complicate monitoring for drug side effects.
CONCLUSIONS
Clear challenges exist in selecting ZIKV therapeutics for CZD prevention, as well as in designing trials. These issues may resurface in a future epidemic of a related or unrelated pathogen. Table 2 summarizes key considerations and recommendations.
Trials of ZIKV therapeutics in pregnancy raise specific ethical challenges for the fetus and mother. The risk for teratogenicity needs to be balanced against the risk for congenital disease due to ZIKV infection. Defining the fetal populations at greatest risk for severe malformations therefore is critical. Because symptoms of maternal ZIKV infection generally are mild (7), using a drug that poses a substantial risk for serious morbidity or mortality to the mother would be unethical. An ethical framework is needed to address this issue. Ongoing drug discovery and development should be accompanied by preemptive work to produce clinical trial protocols that are resilient to our current knowledge limits and acceptable to the population most at risk. The target product profile should be low risk and acceptable to the mother, low risk to the fetus, highly effective in preventing adverse fetal outcomes, and practical for widespread clinical use in resource-limited settings.
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Table 2. Key Considerations and Recommendations
Product development should focus on targeting viral replication/survival rather than the host immune response. Drug repurposing of antiviral small molecules against the Flaviviridae family should be a first approach. Nonhuman primate models should be used to investigate teratogenic drug risks given the limitations of rodents as models of human CNS development. Nonengineered PSAs are already used to prevent some infection-related congenital syndromes, have an acceptable safety profile, and may be suitable phase 2 candidates. The donor pool for anti-ZIKV antibodies should be screened for antibodies against other flaviviruses to minimize the risk for antibody-dependent enhancement. Multiple regular doses of therapy may be required to prevent congenital malformations given the possibility of viral latent reservoirs, and a 3-group trial design should be considered. Initial trials should focus on symptomatic pregnant (first-trimester and early second-trimester) women with positive results on blood PCR testing. Ideally only women who present within 72 h of symptom onset should initially be targeted. Secondary study end points should include screening for various congenital malformations and neuroimaging assessments. Secondary study end points should include neurodevelopmental screening assessments, including vision and hearing, during the first few years of life. The success of therapy should be judged not exclusively by binary outcomes, such as the presence or absence of microcephaly, but also by degree of severity. The identification of the virus in amniotic fluid or congenital malformations in the context of ongoing therapy should not necessarily imply treatment failure until the degree of disease severity can be characterized. Consensus and standards therefore are required for disease definitions and classifications, as well as for identifying congenital malformations secondary to therapy. The target product profile must be low risk to the mother and the fetus and effective in preventing adverse fetal outcomes. CNS = central nervous system; PCR = polymerase chain reaction; PSAs = pathogen-specific antibodies; ZIKV = Zika virus.
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